BTK and B-cell chronic lymphocytic leukemia: The BCR signaling pathway is involved in the pathogenesis of CLL, and drugs that inhibit Bruton’s tyrosine kinase (BTK) and phosphoinositide 3′-kinase (PI3K) are the standard of care when treating CLL.